Compare MBIO & QUCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBIO | QUCY |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | Germany |
| Employees | N/A | 13 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 5.9M |
| IPO Year | 2023 | 2021 |
| Metric | MBIO | QUCY |
|---|---|---|
| Price | $0.60 | $3.59 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 34.2K | ★ 30.0M |
| Earning Date | 05-13-2026 | 06-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 98.99 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $74.34 |
| Revenue Next Year | N/A | $171.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.53 | $0.30 |
| 52 Week High | $7.00 | $3.97 |
| Indicator | MBIO | QUCY |
|---|---|---|
| Relative Strength Index (RSI) | 25.57 | 93.25 |
| Support Level | $0.53 | $0.39 |
| Resistance Level | $0.80 | N/A |
| Average True Range (ATR) | 0.03 | 0.46 |
| MACD | -0.01 | 0.30 |
| Stochastic Oscillator | 2.74 | 67.06 |
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.